<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and T-cell large granular lymphocytic disease (T-LGL) are <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> disorders </plain></SENT>
<SENT sid="1" pm="."><plain>Successful use of <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> to treat cytopenia in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and LGL suggests a common pathophysiology for the two conditions </plain></SENT>
<SENT sid="2" pm="."><plain>Of 100 patients with initial diagnoses of either <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or T-LGL referred to the National Institutes of Health for immunosuppressive treatment of cytopenia, nine had characteristics of both T-LGL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (T-LGL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Fifteen patients with T-LGL received cyclosporin (CSA) (10 responses) </plain></SENT>
<SENT sid="4" pm="."><plain>Eight out of nine patients with T-LGL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> received CSA (two responses) and one patient received ATG (one response) </plain></SENT>
<SENT sid="5" pm="."><plain>Of 76 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, eight received CSA (one response) and 68 received ATG (21 responses) </plain></SENT>
<SENT sid="6" pm="."><plain>The response to immunosuppression was significantly lower in patients with T-LGL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> than in patients with T-LGL disease alone (28% vs. 66%, P = 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>The proportion of T-helper cells and T-suppressor cells with an activated phenotype (HLA-DR(+)) was increased in patients with T-LGL, T-LGL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, but the increase in activated T-suppressor cells in patients with T-LGL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was not statistically significant </plain></SENT>
<SENT sid="8" pm="."><plain>Autoreactive T cells may suppress haematopoiesis and contribute to the cytopenia in T-LGL and some patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, leading to T-LGL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The lower response rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or T-LGL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> to immunosuppression, compared with T-LGL alone, may reflect the older age and intrinsic stem cell abnormalities in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and T-LGL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>